Table 2.
SUMOylation in different kinds of cancers.
| Components | Expression | Effects on cancers |
|---|---|---|
| SUMO1, SUMO2/3 | Upregulated | Silencing the expression of SUMO1 and SUMO 2/3 impairs cell growth and DNA synthesis in glioblastoma [141]. SUMO2/3 is critical for proliferation of Myc-driven lymphoma [123]. |
|
| ||
| SAE1 | Upregulated | SAE1 is positively related with lymph node metastasis of lung adenocarcinomas [121]. SAE1 is important for proliferation of Myc-driven lymphoma [123]. SAE1 promotes the progression of hepatocellular carcinoma [1]. |
|
| ||
| SAE2 | Upregulated | SAE2 can maintain the malignancy and reduce the chemotherapy sensitivity in SCLC [122]. SAE2 is critical for proliferation of Myc-driven lymphoma [123]. |
|
| ||
| Ubc9 | Upregulated | Negatively associated with survival rate of multiple myeloma [112]. Critical for proliferation of Myc-driven lymphoma [123]. Involves in human lung tumorigenesis [142]. Inversely correlated with the sensitivity of chemotherapy and prognosis of breast cancer [126]. Serves as an important molecule in melanoma-positive lymph nodes [128]. |
|
| ||
| PIAS1 | Upregulated | Negatively associated with survival rate of multiple myeloma [112]. Promotes breast tumorigenesis by selectively silencing the epigenetic genes [130]. Overexpressed PIAS1 is correlated with the development of colon cancer [143]. |
|
| ||
| PIAS3 | Upregulated | Increased expression of PIAS3 was observed in lung, breast, prostate, colon-rectum, and brain tumors [144]. |
|
| ||
| PIAS4 | Upregulated | Promotes the hypoxia-dependent EMT by regulating the transcriptional activity of SIRT1 [132]. Serves as an activator of hypoxia pathway in pancreatic cancer cells [133]. |
|
| ||
| SENP1 | Upregulated | Promotes the invasion of neuroblastoma by regulating the expression of MMP2, MMP9, and CDH1 [137]. Essential for the cell proliferation and migration of triple-negative breast cancer in vitro [145]. Increased level of SENP1 mRNA is correlated with cancer recurrence of bladder cancer [134]. |
|
| ||
| SENP2 | Downregulated | Limiting the expression of MMP13 and repressing the invasion and migration of bladder cancer [138]. Inhibiting the activation of NF-κB pathway and improving the sensitivity of breast cancer cells to doxorubicin [146]. |
|
| ||
| SENP3 | Upregulated | Associated with the differentiation of oral squamous cell carcinoma [139]. Regulating cell proliferation by the deSUMOylation of PML under oxidative stress in colon adenocarcinoma [147]. SENP3 regulates the activity of nuclear Nrf2 under reactive oxygen species stress induced by cisplatin in laryngeal carcinoma [148]. |
|
| ||
| SENP5 | Upregulated | Subcellular location of SENP5 is associated with differentiation of oral squamous cell carcinoma [149]. SENP5 promotes breast cancer invasion by mediating TGFβRI SUMOylation [140]. |